Injection of nanoparticle has proven effective in mouse models, researchers say
Researchers at Tel Aviv University have developed a novel nano-vaccine for melanoma, the most aggressive type of skin cancer. Their innovative approach has so far proven effective in preventing the development of melanoma in mouse models and in treating primary tumors and metastases that result from melanoma.
The focus of the research is on a nanoparticle that serves as the basis for the new vaccine. The study was led by Prof. Ronit Satchi-Fainaro, chair of the Department of Physiology and Pharmacology and head of the Laboratory for Cancer Research and Nanomedicine at TAU’s Sackler Faculty of Medicine, and Prof. Helena Florindo of the University of Lisbon while on sabbatical at the Satchi-Fainaro lab at TAU; it was conducted by Dr. Anna Scomparin of Prof. Satchi-Fainaro’s TAU lab and postdoctoral fellow Dr. João Conniot. The results were published on August 5 in Nature Nanotechnology.
Melanoma develops in the skin cells that produce melanin or skin pigment. “The war against cancer in general, and melanoma in particular, has advanced over the years through a variety of treatment modalities, such as chemotherapy, radiation therapy and immunotherapy; but the vaccine approach, which has proven so effective against various viral diseases, has not materialized yet against cancer,” says Prof. Satchi-Fainaro. “In our study, we have shown for the first time that it is possible to produce an effective nano-vaccine against melanoma and to sensitize the immune system to immunotherapies.”
The researchers harnessed tiny particles, about 170 nanometers in size, made of a biodegradable polymer. Within each particle, they “packed” two peptides — short chains of amino acids, which are expressed in melanoma cells. They then injected the nanoparticles (or “nano-vaccines”) into a mouse model bearing melanoma.
“The nanoparticles acted just like known vaccines for viral-borne diseases,” Prof. Satchi-Fainaro explains. “They stimulated the immune system of the mice, and the immune cells learned to identify and attack cells containing the two peptides — that is, the melanoma cells. This meant that, from now on, the immune system of the immunized mice will attack melanoma cells if and when they appear in the body.”
The researchers then examined the effectiveness of the vaccine under three different conditions.
First, the vaccine proved to have prophylactic effects. The vaccine was injected into healthy mice, and an injection of melanoma cells followed. “The result was that the mice did not get sick, meaning that the vaccine prevented the disease,” says Prof. Satchi-Fainaro.
Second, the nanoparticle was used to treat a primary tumor: A combination of the innovative vaccine and immunotherapy treatments was tested on melanoma model mice. The synergistic treatment significantly delayed the progression of the disease and greatly extended the lives of all treated mice.
Finally, the researchers validated their approach on tissues taken from patients with melanoma brain metastases. This suggested that the nano-vaccine can be used to treat brain metastases as well. Mouse models with late-stage melanoma brain metastases had already been established following excision of the primary melanoma lesion, mimicking the clinical setting. Research on image-guided surgery of primary melanoma using smart probes was published last year by Prof. Satchi-Fainaro’s lab.
“Our research opens the door to a completely new approach — the vaccine approach — for effective treatment of melanoma, even in the most advanced stages of the disease,” concludes Prof. Satchi-Fainaro. “We believe that our platform may also be suitable for other types of cancer and that our work is a solid foundation for the development of other cancer nano-vaccines.”
The Latest on: Melanoma
via Google News
The Latest on: Melanoma
- Increased survival with eye melanoma in clinical trialon August 27, 2021 at 8:32 am
Once it has spread (metastasized), uveal (intraocular or eye) melanoma — an unusual form of cancer — has a very high mortality rate. In a study published in Nature Communications, researchers and ...
- Gut Bacteria Linked to Immunotherapy Response, Toxicity in Melanoma Patientson August 27, 2021 at 5:00 am
Bacteroides intestinalis and Intestinibacter bartlettii were significantly enriched in patients who experienced severe toxicity.
- Clinical trial: New combination treatment for eye melanoma increased patient survivalon August 27, 2021 at 4:55 am
Once it has spread, uveal (intraocular or eye) melanoma—an unusual form of cancer—has a very high mortality rate. In a study published in Nature Communications, researchers and doctors at the ...
- Prior Treatment Confers Reduced Responses With Adoptive Transfer of TIL Therapy in Metastatic Melanomaon August 26, 2021 at 1:00 pm
Prior treatment with PD-1 or MAPK inhibitors resulted in lower objective response rates with adoptive cell transfer of autologous tumor-infiltrating lymphocytes in patients with metastatic melanoma vs ...
- FDA Accepts Biologics License Application for Tebentafusp in Metastatic Uveal Melanomaon August 25, 2021 at 9:00 am
Tebentafusp has demonstrated promising responses in metastatic uveal melanoma, leading to FDA and European Medicines Agency approval of a biologics license application and marketing authorization ...
- Spotting the signs of deadly melanoma skin cancerson August 23, 2021 at 9:08 am
Regular skin checks to look for signs of melanoma could save your life. Self-exams for the deadliest type of skin cancer should be done at least once a month in a well-lit room in front of a ...
- Melanoma Cancer Market Size 2021, Cost Analysis, Revenue and Gross Margin Analysis with Its Important Types and Application, Forecast to 2027on August 23, 2021 at 3:03 am
Aug (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry" “Melanoma Cancer Market” report 2021 ...
- Researchers Assess ICI Resistance in Melanoma Treatmenton August 22, 2021 at 8:30 am
In a review published in Biomedicines, researchers outlined the primary and acquired tumor resistance mechanisms to immune checkpoint inhibitors (ICIs) among individuals with melanoma, and assessed ...
- ESPN analyst Dick Vitale has melanoma skin cancer removed: 'I was a little shook up'on August 21, 2021 at 2:46 pm
ESPN college basketball analyst Dick Vitale had a patch of melanoma, a form of skin cancer, removed from just above his nose.
- This 27-Year-Old On TikTok Who Is Dying From Melanoma Wants Everyone To Know Her Story So It Doesn't Happen To Themon August 21, 2021 at 4:31 am
When 27-year-old Kassidy Pierson was around 18, she started to notice some changes to a mole on her inner thigh that she'd had her entire life. Its shape, size, and color were shi ...
via Bing News